ÂÜÀòÂÒÂ×

Fulvio leads the company’s discovery and translational research activities. In this capacity, he will be responsible for expanding the company’s pipeline into larger indications.

He joined Orchard Therapeutics from Smart Immune where he served as a chief scientific officer. Previously, Fulvio was senior vice president of translational science at Audentes Therapeutics in San Francisco, where he was responsible for advancing the company’s pipeline from discovery to clinical development overseeing molecular biology, in vivo pharmacology, bioinformatics, and bioanalytics. Prior to joining Audentes, Fulvio was a chief scientific officer of Genethon in Évry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases. Earlier in his career, he held various positions at the Center for Regenerative Medicine of the University of Modena, Molmed SpA, Genera SpA, and the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy.

Fulvio is a member of the European Molecular Biology Association, a past member of the Board of the American Society of Gene and Cell Therapy, and a member of the editorial board of many international journals in the fields of genetics, molecular biology, and gene therapy. Fulvio earned a Ph.D. in medical genetics at the University of Rome School of Medicine and has published more than 200 articles in major international journals. He also serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia in Modena, Italy.